Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291796 | 1.00 | CYP3A4 (0.50) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL2442693 | 1.00 | CYP3A4 (0.50) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL30569380 | 0.98 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2460929 | 0.98 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2460925 | 0.98 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2459210 | 0.87 | TSHR (0.41) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2459204 | 0.87 | TSHR (0.41) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2461749 | 0.85 | CYP3A4 (0.40) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL2461746 | 0.85 | CYP3A4 (0.40) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL30877547 | 0.82 | CYP3A4 (0.47) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8039470-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| CN-101553482-A | Kinase inhibitor compounds | XCOVERY INC (US) | 2009-10-07 | — | — | CN | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2008033562-A2 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CYP3A4 4408/4885TSHR 4114/4885TDP1 794/4885 |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | CYP3A4 4408/4885TSHR 4114/4885TDP1 794/4885 |
| US-20100261665-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CYP3A4 4408/4885TSHR 4114/4885TDP1 794/4885 |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | CYP3A4 4408/4885TSHR 4114/4885TDP1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.